See every side of every news story
Published loading...Updated

Gennova Biopharmaceuticals expands CEPI partnership for Nipah virus saRNA vaccine development - Express Pharma

Summary by Express Pharma
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, is developing a self-amplifying mRNA (saRNA) vaccine for the Nipah virus. The project is backed by an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $13.38 million in funding. Gennova will collaborate with Houston Methodist Research Institute (HMRI), a CEPI partner based in the United States, to integrate artificia…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Express Pharma broke the news in on Tuesday, April 1, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.